, Volume 108, Issue 1–2, pp 27–32 | Cite as

Effect of ACTH, adrenalectomy and the combination treatment on the density of 5-HT2 receptor binding sites in neocortex of rat forebrain and 5-HT2 receptor-mediated wet-dog shake behaviors

  • Yasukazu Kuroda
  • Masahiko Mikuni
  • Tetsuo Ogawa
  • Kiyohisa Takahashi
Original Investigations


The effect of ACTH and/or adrenalectomy on serotonin (5-HT)2 receptor binding sites was evaluated in the neocortex of rat forebrain. One day after the adrenalectomy or sham operation, ACTH (50 µg/day) was injected subcutaneously into adult male SD rats for 10 consecutive days. Saturation analysis showed that subchronic ACTH treatment significantly increased the Bmax values for3H-ketanserin binding without any change in the Kd values. Moreover, this ACTH-induced increase in the Bmax values was prevented by adrenalectomy. The concentrations of 5-HT and 5-hydroxyindole acetic acid (5-HIAA) measured by HPLC-ECD were not altered by these manipulations. Ten-day administration of corticosterone (20 and 50 mg/kg) also increased 5-HT2 receptor density in the neocortex of rat forebrain. 5-HT2 (and 5-HT1C) receptor agonist, (±)DOI-induced wet-dog shakes in ACTH and/or adrenalectomy-treated rats were also examined. Ten-day administration of ACTH enhanced (±)DOI-induced wet-dog shakes and this increase was prevented by adrenalectomy. These results indicate that subchronic adrenocorticotropinadrenal axis activation of rats increases both the number of 5-HT2 receptors in neocortex of forebrain and the wet-dog shake responses induced by (±)DOI.

Key words

Serotonin-2 (5-HT2) binding site Ketanserin ACTH Corticosterone Adrenalectomy DOI Wet-dog shakes 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arango V, Ernsberger P, Marzuk PM, Chen J-S, Tierney H, Stanley M, Reis DJ, Mann JJ (1990) Autoradiographic demonstration of increased serotonin 5-HT2 and β-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 47:1038–1047PubMedGoogle Scholar
  2. Arnt J, Hyttel J (1989) Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol 161:45–51Google Scholar
  3. Arora RC, Meltzer HY (1989a) Increased serotonin-2(5-HT2) receptor binding as measured by3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. Life Sci 44:725–734CrossRefPubMedGoogle Scholar
  4. Arora RC, Meltzer HY (1989b) Serotonergic measures in the brain of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 146:730–736PubMedGoogle Scholar
  5. Bedard P, Pycock CJ (1977) “Wet-dog” shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology 16:663–670CrossRefPubMedGoogle Scholar
  6. Biegon A, Weizman A, Karp L, Ram A, Tiano S, Wolff M (1987) Serotonin 5-HT2 receptor binding on blood platelets — a peripheral marker for depression? Life Sci 41:2485–2492CrossRefPubMedGoogle Scholar
  7. Blackshear MA, Sanders-Bush E (1980) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221:303–308Google Scholar
  8. Blackshear MA, Steranka LR, Sanders-Bush E (1981) Multiple serotonin receptors: regional distribution and effect of raphe lesions. Eur J Pharmacol 76:325–334CrossRefPubMedGoogle Scholar
  9. Carroll BJ, Curtis GC, Mendels J (1976) Neuroendocrine regulation in depression. I: Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 33:1039–1044PubMedGoogle Scholar
  10. Cheetham SC, Crompton MR, Katona CLE, Horton RW (1988) Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res 443:272–280CrossRefPubMedGoogle Scholar
  11. Clements-Jewery S, Robson PA (1982) Intact 5-HT neuroterminals are not required for 5-HT2 receptor down-regulation by amitriptyline. Neuropharmacology 21:725–727CrossRefPubMedGoogle Scholar
  12. Cohen SI (1980) Cushing's syndrome: a psychiatric study of 29 patients. Br J Psychiatry 136:120–124PubMedGoogle Scholar
  13. Crow TJ, Cross AJ, Cooper SJ, Deakin JFW, Ferrier IN, Johnson JA, Joseph MH, Owen F, Poulter M, Lofthouse R, Corsellis JAN, Chambers DR, Blessed G, Perry EK, Perry RH, Tomlinson BE (1984) Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 23:1561–1569CrossRefPubMedGoogle Scholar
  14. Davies AO, Lefkowitz RJ (1980) Corticosterone-induced differential regulation of β-adrenergic receptors in circulating human polymorphonuclear leukocytes and mononuclear leukocytes. J Clin Endocrinol Metab 51:599–605PubMedGoogle Scholar
  15. Dumbrille-Ross A, Tang SW, Coscina DV (1982) Lack of effect of raphe lesions on serotonin S2 receptor changes by amitriptyline and desmethylimipramine. Psychiatry Res 7:145–151CrossRefPubMedGoogle Scholar
  16. Eison AS, Yokka FD, Gianutsos G (1988) Noradrenergic denervation alters serotonin 2-mediated behavior but not serotonin 2 receptor number in rats: modulatory role of beta adrenergic receptors. J Pharmacol Exp Ther 246:571–577PubMedGoogle Scholar
  17. Foster SJ, Harden TK (1980) Dexamethasone increases β-adrenoreceptor density in human astrocytoma cells. Biochem Pharmacol 29:2151–2153CrossRefPubMedGoogle Scholar
  18. Fraser CM, Venter JC (1980) The synthesis of β-adrenergic receptors in cultured human lung cells: induction by glucocorticoids. Biochem Biophys Res Commun 94:390–397CrossRefPubMedGoogle Scholar
  19. Gold PW, Goodwin FK, Chrousos GP (1988): Clinical and biochemical manifestations of depression: relation to the neurobiology of stress II. N Engl J Med 319:413–420PubMedGoogle Scholar
  20. Hall H, Ross SB, Sällemark M (1984) Effect of destruction of central noradrenergic and serotonergic nerve terminals by systemic neurotoxins on the long term effects of antidepressants on β-adrenoceptors and 5-HT2 binding sites in the rat cerebral cortex. J Neural Transm 59:9–23CrossRefPubMedGoogle Scholar
  21. Handley SL, Singh L (1986) The modulation of head-twitch behaviour by drugs acting on beta-adrenoreceptors: evidence for the involvement of both beta1- and beta2-adrenoreceptors. Psychopharmacology 88:320–324CrossRefPubMedGoogle Scholar
  22. Haskett RF (1985) Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry 142:911–916PubMedGoogle Scholar
  23. Heaton JCP, Njung'e K, Handley SL (1988) Behavioural profile of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a selective 5-HT2 agonist. Br J Pharmacol 94:388PGoogle Scholar
  24. Kelly WF, Checkley SA, Bender DA (1980) Cushing's syndrome, tryptophan and depression. Br J Psychiatry 136:125–132PubMedGoogle Scholar
  25. Kendall DA, Duman R, Slopis J, Enna SJ (1982) Influence of adrenocorticotropine hormone and yohimbine on antidepressant-induced declines in rat brain neurotransmitter receptor binding and function. J Pharmacol Exp Ther 222:566–571PubMedGoogle Scholar
  26. Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H]ketanserin (R 41 468), a selective3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution and functional role. Mol Pharmacol 21:301–314PubMedGoogle Scholar
  27. Leysen JE, Van Gompel P, Verwimp M, Niemegeers CJE (1983) Role and localization of serotonin 2 (S2)-receptor-binding sites: Effect of neuronal lesions. In: Mandel P, DeFeudis FV (eds) CNS receptors-from molecular pharmacology to behavior. Raven Press, New York, pp 373–383Google Scholar
  28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  29. McBride PA, Brown RP, Demeo M, Kelip J, Stanley M, Mann JJ (1987) Platelet 5HT2 receptors: Depression and suicide. 140th Annual Meeting of the American Psychiatric AssociationGoogle Scholar
  30. McKeith IG, Marshall EF, Ferrier IN, Armstrong MM, Kennedy WN, Perry RH, Perry EK, Eccleston D (1987) 5-HT receptor binding in post-mortem brain from patients with affective disorder. J Affect Disord 13:67–74CrossRefPubMedGoogle Scholar
  31. Mann JJ, Stanley M, McBride PA, McEwen BS (1986) Increased serotonin 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 43:954–959PubMedGoogle Scholar
  32. Martire M, Pistritto G, Preziosi P (1989) Different regulation of serotonin receptors following adrneal hormone imbalance in the rat hippocampus and hypothalamus. J Neural Transm 78:109–120CrossRefPubMedGoogle Scholar
  33. Mikuni M, Kusumi I, Kagaya A, Kuroda Y, Mori H, Takahashi K (1991) Increased 5-HT-2 receptor function as measured by serotonin-stimulated phosphoinositide hydrolysis in platelets of depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 15:49–61CrossRefPubMedGoogle Scholar
  34. Mikuni M, Kagaya A, Takahashi K, Meltzer HY (1992) Serotonin but not norepinephrine-induced calcium mobilization of platelets is enhanced in affective disorders. Psychopharmacology 106:311–314CrossRefPubMedGoogle Scholar
  35. Nemeroff CB, Widerlöv E, Bissette G (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342–1344Google Scholar
  36. Nishikawa T, Mataga N, Takashima M, Toru M (1983) Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur J Pharmacol 88:195–203CrossRefPubMedGoogle Scholar
  37. Owen F, Chambers DR, Cooper SJ, Crow TJ, Johnson JA, Lofthouse R, Poulter M (1986) Serotonergic mechanisms in brains of suicide victims. Brain Research 362:185–188CrossRefPubMedGoogle Scholar
  38. Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM (1990) Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 28:215–222CrossRefPubMedGoogle Scholar
  39. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, SydneyGoogle Scholar
  40. Peroutka SJ, Snyder SH (1980a) Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210:88–90PubMedGoogle Scholar
  41. Peroutka SJ, Snyder SH (1980b) Regulation of serotonin2 (5-HT2) receptors labeled with3H spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther 215:582–587PubMedGoogle Scholar
  42. Pranzatelli MR (1988) Effect of antiepileptic and antimyoclonic drugs on serotonin receptors in vitro. Epilepsia 29:412–419PubMedGoogle Scholar
  43. Pranzatelli MR (1990a) Evidence for involvement of 5-HT2 and 5-HT1c receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2(DOI). Neurosci Lett 115:74–80CrossRefPubMedGoogle Scholar
  44. Pranzatelli MR (1990b) In vivo and in vitro effects of adrenocorticotropic hormone on serotonin receptors in neonatal rat brain. Dev Pharmacol Ther 12:49–56Google Scholar
  45. Rodan SB, Rodan GA (1986) Dexamethasone effects on β-adrener gic receptors and adenylate cyclase regulatory proteins Gs and Gi in ROS 17/2.8 cells. Endocrinology 118:2510–2518PubMedGoogle Scholar
  46. Scatchard G (1949) The attraction of proteins for small ions and molecules. Ann NY Acad Sci 51:660–672Google Scholar
  47. Spillane JD (1951) Nervous and mental disorders in Cushing's syndrome. Brain 74:72–94PubMedGoogle Scholar
  48. Stanley M, Mann JJ (1983) Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet i:214–216CrossRefGoogle Scholar
  49. Stockmeier CA, Kellar KJ (1986) In vivo regulation of serotonin-2 receptor in rat brain. Life Sci 38:117–127CrossRefPubMedGoogle Scholar
  50. Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN (1990) 5HT2 receptor changes in major depression. Biol Psychiatry 27:489–496CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Yasukazu Kuroda
    • 1
    • 2
  • Masahiko Mikuni
    • 1
  • Tetsuo Ogawa
    • 1
  • Kiyohisa Takahashi
    • 1
  1. 1.Division of Mental Disorder ResearchNational Institute of Neuroscience, NCNPTokyoJapan
  2. 2.Department of NeuropsychiatryTokyo Medical and Dental University School of MedicineTokyoJapan

Personalised recommendations